| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8723821 | Nutrition | 2018 | 28 Pages |
Abstract
Three months of treatment with cholecalciferol achieved sufficient 25(OH)D3 levels and can regulate late-activated T-cells and monocytes in patients with AD. Explorative analysis revealed potential genetic contributions. This pilot trial provides novel insights about immunomodulation in AD.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Marissa Ph.D., Natalie Ph.D., Dimitra M.D., Firouzeh M.Sc., Sabine Ph.D., Ralf Ph.D., Eva Ph.D., Ulrike Ph.D., Eystein S. M.D., Ph.D., Klaus M.D., Ph.D.,